Saxenda (liraglutide 3 mg) Letter of Medical Necessity
Saxenda (liraglutide 3 mg) is a daily GLP-1 receptor agonist for chronic weight management and the most established anti-obesity GLP-1 option for adolescents. Coverage hinges first on whether the plan covers weight-loss drugs at all, then on BMI, comorbidity, and lifestyle-program documentation. Medicare Part D excludes drugs used for weight loss by statute.
FDA-Approved Indications
- ● chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity
- ● chronic weight management in pediatric patients 12 years and older with obesity
Why Saxenda Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Weight-loss medications excluded from the plan benefit
- 2. BMI and weight-related comorbidities not documented
- 3. Participation in a reduced-calorie diet and physical activity program not documented
- 4. Continuation request without documented weight loss (≥4% at 16 weeks in adults)
- 5. Concurrent use with another GLP-1 receptor agonist
What to Include in a Saxenda Letter of Medical Necessity
Document height, weight, and BMI with date, weight-related comorbidities (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea), participation in a structured diet and exercise program, prior weight-management attempts, and for renewals, the percent weight loss achieved since initiation. For adolescents, document BMI percentile per CDC growth charts.
Key clinical evidence to cite:
- ✓ SCALE Obesity and Prediabetes trial — clinically meaningful weight loss vs placebo over 56 weeks
- ✓ SCALE Diabetes trial in adults with type 2 diabetes and overweight/obesity
- ✓ SCALE Teens trial — BMI reduction in adolescents aged 12 to 17 with obesity
- ✓ Daily dosing alternative when weekly semaglutide or tirzepatide is unavailable or not tolerated
Relevant guidelines:
- 📖 AACE 2025 Obesity Clinical Practice Guideline
- 📖 AGA 2022 Obesity Pharmacotherapy Guideline
- 📖 AAP 2023 Pediatric Obesity Clinical Practice Guideline
Saxenda Prior Authorization Criteria
Standard criteria across major US payers for Saxenda. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Saxenda
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Saxenda Prior Authorization FAQ
Why was my Saxenda prior authorization denied?
The most common denial reasons for Saxenda are: Weight-loss medications excluded from the plan benefit; BMI and weight-related comorbidities not documented; Participation in a reduced-calorie diet and physical activity program not documented; Continuation request without documented weight loss (≥4% at 16 weeks in adults); Concurrent use with another GLP-1 receptor agonist.
What should a Saxenda Letter of Medical Necessity include?
Document height, weight, and BMI with date, weight-related comorbidities (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea), participation in a structured diet and exercise program, prior weight-management attempts, and for renewals, the percent weight loss achieved since initiation. For adolescents, document BMI percentile per CDC growth charts.
Which payers cover Saxenda?
Saxenda is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicaid, though formulary tier and prior authorization criteria vary.